Anzeige
Mehr »
Login
Mittwoch, 22.01.2025 Börsentäglich über 12.000 News von 682 internationalen Medien
STRONG BUY! Kurs eskaliert - A Star is Born!
Anzeige

Indizes

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Aktien

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Xetra-Orderbuch

Fonds

Kurs

%

Devisen

Kurs

%

Rohstoffe

Kurs

%

Themen

Kurs

%

Erweiterte Suche

WKN: A0MVRB | ISIN: FR0010481960 | Ticker-Symbol: 871
Frankfurt
21.01.25
12:26 Uhr
62,20 Euro
0,00
0,00 %
Branche
Immobilien
Aktienmarkt
CAC Mid 60
1-Jahres-Chart
ARGAN SA Chart 1 Jahr
5-Tage-Chart
ARGAN SA 5-Tage-Chart
RealtimeGeldBriefZeit
60,7062,1007:44
GlobeNewswire (Europe)
263 Leser
Artikel bewerten:
(1)

ARGAN: S&P strengthened ARGAN's "Investment Grade" status with a "Stable" outlook for its "BBB-" rating

Finanznachrichten News

Press release - Neuilly-sur-Seine, Monday, May 13, 2024 - 5.45 pm

S&P strengthened ARGAN's "Investment Grade" status with a "Stable" outlook for its "BBB-" rating

ARGAN, the only French real estate company specializing in the DEVELOPMENT & RENTAL OF PREMIUM WAREHOUSES listed on EURONEXT and leading player of its market, announced that the outlook on its "BBB-" long-term issuer credit rating was raised to "Stable" by S&P Global Ratings.

S&P Global Ratings raised the outlook on ARGAN's "BBB-" from "Negative" to "Stable". This credit rating update comes after ARGAN successfully led a capital increase in the amount of €150 million1, which was launched and finalized on April 23, as part a move to strengthen our development and debt reduction plan.

In its report, S&P Global Ratings stressed more particularly:

  • the faster than previously anticipated improvement in debt ratios by the end of 2024, which ARGAN targets to bring to 44 % regarding its LTV2 ratio and to 9.5x for its net debt to EBITDA;
  • an adequate liquidity position, with no refinancing needs for the years 2024 and 2025; and
  • a portfolio of premium assets that generate stable and predictable cash flows, in a supportive French logistics real estate sector.

More generally, this upgrade testifies to the adequacy of the Group's strategy for mastered growth and strong debt reduction as well as increased trust from financial markets in ARGAN's name, reinforced by steady and transparent financial communication.

The rating is available on the website of S&P Global Ratings (www.standardandpoors.com).

2024 financial calendar (Publication of the press release after closing of the stock exchange)

  • July 1: Net sales of 2nd quarter 2024
  • July 24: Half-year results 2024
  • October 1: Net sales of 3rd quarter 2024

2025 financial calendar (Publication of the press release after closing of the stock exchange)

  • January 3: Net sales of 4th quarter 2024
  • January 16: Annual results 2024
  • March 20: General Assembly 2025

About ARGAN

ARGAN is the only French real estate company specializing in the DEVELOPMENT & RENTAL OF PREMIUM WAREHOUSES listed on EURONEXT and is the leading player of its market. Building on a unique client-tenant-centric approach, ARGAN builds pre-let PREMIUM warehouses for blue-chip clients and supports them throughout all project phases from the development milestones to the rental management.
Profitability, tight control over our debt and sustainability are at the heart of ARGAN's DNA. Its strongly proactive ESG policy has very concrete results with our Aut0nom® concept, the "in-use" Net Zero warehouse.
As of today, our portfolio represents 3.6 million sq.m, across about a hundred warehouses, exclusively located in the continental part of France. This portfolio is valued €3.7 billion as at December 31, 2023 for a yearly rental income of about €200 million in 2024.
ARGAN is a listed real estate investment company (French SIIC), on Compartment A of Euronext Paris (ISIN FR0010481960 - ARG) and is included in the Euronext SBF 120, CAC All-Share, EPRA Europe and IEIF SIIC France indices.
www.argan.fr



Francis Albertinelli - CFO
Aymar de Germay - General Secretary
Samy Bensaid - Head of Investor Relations
Phone: +33 1 47 47 47 40
E-mail: contact@argan.fr
www.argan.fr




Marlène Brisset - Media relations
Phone: +33 6 59 42 29 35
E-mail: argan@citigatedewerogerson.com


1 For more information, readers are referred to press releases published on April 23 and April 24, 2024, under the "Capital increase" section of the regulated information available on argan.fr.
2 LTV EPRA (excluding duties), assuming a cap. rate of 5.25% excluding duties.


© 2024 GlobeNewswire (Europe)
Gewinner im Megamarkt
Biotechnologie ist eine der bedeutendsten Zukunftstechnologien unserer Zeit. Zahlreiche Biotechnologie- und Pharmakonzerne haben sich unter anderem dem Kampf gegen Tumorerkrankungen verschrieben. Der weltweite Markt für Krebsmedikamente verzeichnet ein stetiges Wachstum. Für das Jahr 2025 wird ein Umsatz von etwa 190,3 Milliarden Euro prognostiziert, mit einer erwarteten jährlichen Wachstumsrate von 6,42% bis 2029, was zu einem geschätzten Marktvolumen von 244,1 Milliarden Euro führen würde.

Wir haben 3 aussichtsreiche Biotechnologieaktien mit Schwerpunkt Erforschung und Entwicklung von Wirkstoffen gegen Tumorerkrankungen ausfindig gemacht, die in den kommenden Monaten und Jahren erhebliches Aufwärtspotenzial versprechen und Vervielfachungspotenzial besitzen.

Fordern Sie jetzt unseren neuen kostenlosen Spezialreport an und erfahren Sie, welche 3 Biotech-Aktien durchstarten und zu Ihrem Börsenerfolg in 2025 beitragen könnten!
Werbehinweise: Die Billigung des Basisprospekts durch die BaFin ist nicht als ihre Befürwortung der angebotenen Wertpapiere zu verstehen. Wir empfehlen Interessenten und potenziellen Anlegern den Basisprospekt und die Endgültigen Bedingungen zu lesen, bevor sie eine Anlageentscheidung treffen, um sich möglichst umfassend zu informieren, insbesondere über die potenziellen Risiken und Chancen des Wertpapiers. Sie sind im Begriff, ein Produkt zu erwerben, das nicht einfach ist und schwer zu verstehen sein kann.